Tylleskar, Ida http://orcid.org/0000-0002-3220-1961
Gjersing, Linn
Bjørnsen, Lars Petter
Braarud, Anne-Cathrine
Heyerdahl, Fridtjof
Dale, Ola
Skulberg, Arne Kristian http://orcid.org/0000-0002-1735-4820
Funding for this research was provided by:
Universitetet i Oslo
Oslo University Hospital
St. Olavs Hospital Universitetssykehuset i Trondheim
Norges Teknisk-Naturvitenskapelige Universitet
Article History
Received: 26 May 2020
Accepted: 31 August 2020
First Online: 5 September 2020
Ethics approval and consent to participate
: The study was approved by The Regional Committee for Medical and Health Research Ethics (REK 2014/140) and was conducted in accordance with the Declaration of Helsinki. Data from January 1st, 2014 to May 31st, 2014, were collected retrospectively and registered anonymously without consent. Waived consent was used for participants included between June 1st, 2014 and December 31st, 2018. They received oral and written information about the study at the time of treatment by emergency medical services and were included unless they asked to be withdrawn from the study on site or contacted the study team later by phone.
: Not applicable.
: NTNU and its subsidiary Technical Transfer Office have signed cooperation and licensing contracts with dne pharma as to seek commercialization of a nasal naloxone formulation. This regulates potential royalties for Ola Dale through NTNU. Dne pharma as has compensated OD for business travel from Trondheim to Oslo and to Lisbon. Arne Kristian Skulberg spoke at a seminar arranged by dne pharma as in Lisbon October 2019 without honorarium or other compensation. The other authors declare no conflicts of interest. Dne pharma as have no role in the study design, data collection, data analysis, data interpretation or writing of this article. Oslo University Hospital has full ownership of the data and results generated in this study.